Yoshindo
- Company typePrivate
- Founded1929
- HeadquartersToyama, Japan
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Yoshindo firmographics
Firmographics- Name
- Yoshindo
- Legal name
- Yoshindo Holdings Inc.
- Website
- https://yoshindo.co.jp
- Company type
- Private
- Founded year
- 1929
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Yoshindo industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Yoshindo is headquartered
LocationHeadquarters
- HQ city
- Toyama
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Yoshindo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels3 records
Yoshindo product offering
Product offeringCore offering
Yoshindo is a Japanese pharmaceutical manufacturer that produces and supplies generic drugs, essential medicines, biopharmaceuticals (including biosimilars), health foods, and infusion/dialysis solutions. The company distributes its products through pharmaceutical wholesalers to hospitals, clinics, and pharmacies across Japan. Yoshindo is also building biosimilar manufacturing capacity using Cytiva's FlexFactory™ platform, targeting antibody drug API production by 2028.
Product overview
Yoshindo Holdings is a pharmaceutical company operating multiple business segments including generic drugs, essential drugs, biopharmaceuticals (biosimilars), health foods, and infusion/dialysis solutions. The company is expanding into biosimilar manufacturing with Cytiva's FlexFactory™ technology, targeting production start by 2028. The portfolio is organized into distinct product categories under unified corporate governance.
Differentiator
Problem solved
Functional benefit
Brands
- FlexFactory™: Biosimilar manufacturing platform implemented in collaboration with Cytiva for producing antibody drug active pharmaceutical ingredients
Products and services
- Generic Drugs (ジェネリック医薬品) Yoshindo's generic pharmaceutical products offering cost-effective alternatives to brand-name medications for hospitals, clinics, pharmacies, and patients in Japan.
- Essential Drugs (エッセンシャルドラッグ) Essential medicines addressing fundamental healthcare needs, supplied to medical institutions across Japan.
- Biopharmaceuticals (バイオ医薬品) Biologic drugs including biosimilars, with a focus on antibody drug active pharmaceutical ingredients for the biopharmaceutical market.
- Health Foods (健康食品) Nutritional and health supplement products supporting consumer wellness, distributed through Yoshindo's healthcare channels.
- Infusion/Dialysis Solutions (輸液・透析液) Intravenous solutions and dialysis fluids for medical treatment, supplied to hospitals and clinics in Japan.
- Biosimilar Manufacturing System (Cytiva FlexFactory™) A comprehensive biosimilar manufacturing system established in Japan with Cytiva's FlexFactory™ technology, targeting production start by 2028 for antibody drug biosimilar active pharmaceutical ingredients.
Companies that use Yoshindo
Customer profileSegments2 records
Ideal customer profiles2 records
Yoshindo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Yoshindo partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CytivacoreYoshindo has established a biosimilar manufacturing system in Japan with support from Cytiva's FlexFactory™ technology. The partnership aims to start production by 2028, focusing on biosimilar active pharmaceutical ingredients for antibody drugs. The collaboration positions Yoshindo to capitalize on significant market growth forecasts in the biosimilar sector.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
Yoshindo competitors and assessment
Company assessmentDirect peers
- Sawai Group Holdings: Sawai is the largest Japanese generic pharmaceutical manufacturer with broad generic and biosimilar activities — directly comparable to Yoshindo's generic and emerging biosimilar focus in the Japan market.
- Towa Pharmaceutical: Towa is a top-tier Japanese generic drug manufacturer with diversified dosage forms and growing biosimilar activity — directly comparable to Yoshindo's generic + biosimilar positioning.
- Nichi-Iko Pharmaceutical: Nichi-Iko is a leading Japanese generic pharmaceutical company with an extensive off-patent portfolio — closely comparable to Yoshindo's generic FDF manufacturing base.
- Fuji Pharma: Fuji Pharma is a Japanese specialty generic and biosimilar manufacturer with a portfolio spanning injectables and biosimilars — directly comparable to Yoshindo's generic and biosimilar activities.
- Mochida Pharmaceutical: Mochida is a mid-sized Japanese pharmaceutical manufacturer with a focus on specialty and biosimilar products — comparable to Yoshindo's diversified generic + biopharma profile.
Broad incumbents
- Kyowa Kirin: Kyowa Kirin is a major Japanese specialty biopharma company with biologic and biosimilar activities — a broader incumbent operating in the same therapeutic categories and Japan market as Yoshindo.
- Chugai Pharmaceutical: Chugai is one of Japan's largest biopharmaceutical companies with a strong biologics franchise — a broader incumbent representative of the competitive landscape for Yoshindo's biosimilar ambitions.
- Daiichi Sankyo: Daiichi Sankyo is a top-tier Japanese pharma major with both innovative and biosimilar operations — a broader incumbent that competes at scale against Yoshindo's biosimilar entry.
- Astellas Pharma: Astellas is a leading Japanese biopharmaceutical company with established biologics and biosimilar capabilities — a broader incumbent in Yoshindo's therapeutic and operational space.
- Takeda Pharmaceutical: Takeda is Japan's largest pharmaceutical manufacturer with global biosimilar and biologic operations — a broader incumbent representative of Japan's ultimate competitive ceiling for Yoshindo.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Yoshindo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yoshindo leadership team
Management profileNumber of profiles
Yoshindo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yoshindo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yoshindo
What does Yoshindo do?
Yoshindo is a Japanese pharmaceutical manufacturer that produces and supplies generic drugs, essential medicines, biopharmaceuticals (including biosimilars), health foods, and infusion/dialysis solutions. The company distributes its products through pharmaceutical wholesalers to hospitals, clinics, and pharmacies across Japan. Yoshindo is also building biosimilar manufacturing capacity using Cytiva's FlexFactory™ platform, targeting antibody drug API production by 2028.
Is Yoshindo a public or private company?
Yoshindo is a private company. It is classified as unknown and is currently operating.
When was Yoshindo founded?
Yoshindo was founded in 1929. It employs 1 to 10 people.
Where is Yoshindo based?
Yoshindo is headquartered in Toyama, Japan, in the Asia region.
Who are Yoshindo's main competitors?
Direct peers on record are Sawai Group Holdings, Towa Pharmaceutical, Nichi-Iko Pharmaceutical, Fuji Pharma and Mochida Pharmaceutical. Broad incumbents are Kyowa Kirin, Chugai Pharmaceutical, Daiichi Sankyo, Astellas Pharma and Takeda Pharmaceutical.
Does Yoshindo have an API?
No public API is recorded for Yoshindo.
What industry is Yoshindo in?
Yoshindo's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.